Diamyd Medical AB (publ) Asset Resilience Ratio
Diamyd Medical AB (publ) asset resilience ratio. Diamyd Medical AB (publ) (DMYD-B) has an Asset Resilience Ratio of 9.77% as of May 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DMYD-B days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Diamyd Medical AB (publ) (2011–2025)
Asset resilience ratio of Diamyd Medical AB (publ) from 2011 to 2025. This chart shows how Diamyd Medical AB (publ)'s Asset Resilience Ratio has changed over time. Read Diamyd Medical AB (publ) balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Diamyd Medical AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Diamyd Medical AB (publ) asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr39.73 Million | 9.77% |
| Total Liquid Assets | Skr39.73 Million | 9.77% |
Asset Resilience Insights
- Limited Liquidity: Diamyd Medical AB (publ) maintains only 9.77% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Diamyd Medical AB (publ) Industry Peers by Asset Resilience Ratio
Compare Diamyd Medical AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Diamyd Medical AB (publ) Asset Resilience Ratio by Year (2011–2025)
Diamyd Medical AB (publ) asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Diamyd Medical AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-08-31 | 78.60% | Skr277.19 Million ≈ $29.83 Million |
Skr352.64 Million ≈ $37.95 Million |
+17.62pp |
| 2024-08-31 | 60.99% | Skr132.37 Million ≈ $14.24 Million |
Skr217.04 Million ≈ $23.36 Million |
-0.70pp |
| 2023-08-31 | 61.69% | Skr126.96 Million ≈ $13.66 Million |
Skr205.81 Million ≈ $22.15 Million |
-5.82pp |
| 2022-08-31 | 67.51% | Skr159.67 Million ≈ $17.18 Million |
Skr236.52 Million ≈ $25.45 Million |
-1.68pp |
| 2021-08-31 | 69.19% | Skr139.38 Million ≈ $15.00 Million |
Skr201.44 Million ≈ $21.68 Million |
-6.97pp |
| 2020-08-31 | 76.16% | Skr68.36 Million ≈ $7.36 Million |
Skr89.76 Million ≈ $9.66 Million |
-0.27pp |
| 2019-08-31 | 76.43% | Skr56.71 Million ≈ $6.10 Million |
Skr74.20 Million ≈ $7.99 Million |
-3.80pp |
| 2018-08-31 | 80.23% | Skr44.11 Million ≈ $4.75 Million |
Skr54.98 Million ≈ $5.92 Million |
-6.67pp |
| 2017-08-31 | 86.90% | Skr85.72 Million ≈ $9.23 Million |
Skr98.65 Million ≈ $10.62 Million |
+3.79pp |
| 2016-08-31 | 83.11% | Skr31.40 Million ≈ $3.38 Million |
Skr37.78 Million ≈ $4.07 Million |
+55.24pp |
| 2015-08-31 | 27.87% | Skr13.00 Million ≈ $1.40 Million |
Skr46.65 Million ≈ $5.02 Million |
+6.39pp |
| 2014-08-31 | 21.48% | Skr10.96 Million ≈ $1.18 Million |
Skr51.02 Million ≈ $5.49 Million |
-29.70pp |
| 2012-08-31 | 51.18% | Skr215.85 Million ≈ $23.23 Million |
Skr421.74 Million ≈ $45.39 Million |
-2.29pp |
| 2011-08-31 | 53.48% | Skr277.86 Million ≈ $29.90 Million |
Skr519.60 Million ≈ $55.92 Million |
-- |
About Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with ty… Read more